Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Clinical and Experimental Rheumatology|September 1, 1996
dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activityG Filaci, I Grasso, P Contini, et al.
Cancer Immunology, Immunotherapy : CII|July 1, 1993
Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancerM Scudeletti, G Filaci, M A Imro, et al.
International Journal of Immunopharmacology|March 1, 1997
S-adenosil-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitroG Filaci, N Pelli, T Sacco, et al.
Tissue Antigens|April 15, 1999
Beta2-micro-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with beta2-micro-associated HLA class I heavy chain levels and HLA phenotypeF Puppo, D Bignardi, P Contini, et al.
AIDS Research and Human Retroviruses|December 9, 1997
Downregulation of HLA class I antigen expression in CD4+ T lymphocytes from HIV type 1-infected individualsF Puppo, S Brenci, O Bosco, et al.
Bone Marrow Transplantation|May 1, 1996
Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHDF Puppo, S Brenci, M Ghio, et al.
Tissue Antigens|June 14, 2000
Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigensF Puppo, S Brenci, P Contini, et al.
European Journal of Immunology|December 23, 1998
Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentationG Filaci, P Contini, I Grasso, et al.
Melanoma Research|August 1, 1997
Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patientC Doucet, R Meazza, C Pottin-Clemenceau, et al.
Rheumatology (Oxford, England)|October 27, 1999
Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapyG Filaci, M Cutolo, M Scudeletti, et al.
Pageof 6